Three Peptides, Three Different Mechanisms
BPC-157, TB-500 (thymosin beta-4), and GHK-Cu are frequently discussed together in tissue-repair research, but they're structurally and mechanistically distinct compounds studied for overlapping — not identical — reasons. Understanding what separates them helps make sense of why each appears in the research literature it does.
| BPC-157 | TB-500 | GHK-Cu | |
|---|---|---|---|
| Structure | 15 amino acids | 43 amino acids | Tripeptide + copper ion |
| Origin | Human gastric juice | Found in nearly all human cells | Human blood plasma |
| Primary mechanism | FAK-paxillin pathway, VEGFR2 upregulation | Actin sequestration (G-actin binding) | Collagen/elastin gene transcription |
| Primary research focus | Gut lining, tendon/ligament healing | Cell migration, wound closure, cardiac models | Skin, connective tissue, wound healing |
| Human trial evidence | None published — animal models only | Some Phase 2 trials (wound healing, dry eye) | Topical/dermatological studies |
BPC-157: Gastric-Derived, Multi-System Effects
BPC-157's research base is built almost entirely on rodent studies, spanning gut protection, tendon and ligament healing, and a scattering of other injury models. Its appeal to researchers lies partly in how broadly it appears to act across otherwise unrelated tissue types — see our full BPC-157 research overview for the mechanistic detail.
TB-500: The Most Clinically Advanced of the Three
Thymosin beta-4, and the synthetic peptide fragment commonly called TB-500, works through a fundamentally different mechanism — regulating the cytoskeletal protein actin, which governs how cells migrate toward injury sites. Notably, TB-500 has actually progressed further into human trials than BPC-157 has: Phase 2 studies in chronic wound healing and dry eye have been conducted, giving it a comparatively stronger — though still limited — human evidence base. A recent scoping review mapping the TB4/TB-500 literature (80 studies identified from an initial 1,772 records) found the evidence weighted toward in vitro and mixed study designs, with most work evaluating TB4 specifically rather than the TB-500 fragment.
GHK-Cu: The Most Established Literature, Narrowest Focus
GHK-Cu has the longest research history of the three, dating to its 1973 isolation, but its evidence base is concentrated specifically in dermatological and connective-tissue contexts rather than the broader systemic effects studied for BPC-157 and TB-500. See our full GHK-Cu research overview for the collagen-synthesis mechanism in detail.
The Honest Summary
These three peptides aren't interchangeable research tools, and none of them should be evaluated as if the others' evidence base applies equally. BPC-157's literature is broad but entirely preclinical. TB-500 has moved furthest into actual human trials of the three. GHK-Cu has the deepest, most mechanistically detailed literature, but the narrowest scope. Each is worth understanding on its own terms.
Availability: Pacific Peptides stocks BPC-157 individually, and all three compounds discussed here together in our GLOW Blend. Each batch is independently tested — results are published on our Lab Results page.
This article is provided for general research and educational purposes. It summarizes published preclinical and clinical literature and does not constitute guidance for human use of any compound. All products referenced are sold strictly for laboratory research use.